Steven Cohen Coherus Bio Sciences, Inc. Transaction History

Point72 Asset Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$3.74 - $5.45 $3.56 Million - $5.19 Million	-952,530 Reduced 99.22%	7,491 $28,000
Q2 2023 Aug 14, 2023	BUY	$3.79 - $8.3 $3.64 Million - $7.97 Million	960,021 New	960,021 $4.1 Million
Q2 2022 Aug 15, 2022	SELL	$5.86 - $13.23 $3.35 Million - $7.57 Million	-572,200 Reduced 80.82%	135,800 $983,000
Q1 2022 May 16, 2022	BUY	$10.92 - $16.41 $4.12 Million - $6.2 Million	377,700 Added 114.35%	708,000 $9.14 Million
Q4 2021 Feb 14, 2022	BUY	$15.81 - $18.99 $5.22 Million - $6.27 Million	330,300 New	330,300 $5.27 Million
Q2 2019 Aug 14, 2019	SELL	$13.1 - $22.1 $12 Million - $20.3 Million	-917,896 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$8.38 - $15.5 $7.69 Million - $14.2 Million	917,896 New	917,896 $12.5 Million
Q4 2018 Feb 14, 2019	SELL	$8.65 - $16.28 $1.3 Million - $2.44 Million	-150,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$14.45 - $20.25 $2.35 Million - $3.3 Million	-162,800 Reduced 52.05%	150,000 $2.48 Million
Q2 2018 Aug 14, 2018	BUY	$10.25 - $17.45 $3.21 Million - $5.46 Million	312,800 New	312,800 $4.38 Million

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $115M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.